GERN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -50.09% compared to Geron's net margin of -49.65%. Geron's return on equity of -46.58% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Geron has a consensus price target of $3.39, signalling upside risk potential of 162.71%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Geron has higher upside potential than NovaBay Pharmaceuticals, analysts believe Geron is more attractive than NovaBay Pharmaceuticals.

Geron has a beta of 0.645, which suggesting that the stock is 35.492% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Geron's net income of -$19.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Geron's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 7.34x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -50.09% compared to Geron's net margin of -60.08%. Geron's return on equity of -46.58% beat Sarepta Therapeutics's return on equity of -20.94%.

Geron has a consensus price target of $3.39, signalling upside risk potential of 162.71%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.16 which suggests that it could grow by 101%. Given that Geron has higher upside potential than Sarepta Therapeutics, analysts believe Geron is more attractive than Sarepta Therapeutics.

Geron has a beta of 0.645, which suggesting that the stock is 35.492% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Geron's net income of -$19.8M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Geron's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 7.34x versus 1.09x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -50.09% compared to Geron's net margin of 11.15%. Geron's return on equity of -46.58% beat Stryker's return on equity of 14.2%.

Geron has a consensus price target of $3.39, signalling upside risk potential of 162.71%. On the other hand Stryker has an analysts' consensus of $422.71 which suggests that it could grow by 8.69%. Given that Geron has higher upside potential than Stryker, analysts believe Geron is more attractive than Stryker.

Geron has a beta of 0.645, which suggesting that the stock is 35.492% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Geron pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Geron quarterly revenues are $39.6M, which are smaller than Stryker quarterly revenues of $5.9B. Geron's net income of -$19.8M is lower than Stryker's net income of $654M. Notably, Geron's price-to-earnings ratio is -- while Stryker's PE ratio is 52.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 7.34x versus 6.46x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -50.09% compared to Geron's net margin of --. Geron's return on equity of -46.58% beat Theriva Biologics's return on equity of --.

Geron has a consensus price target of $3.39, signalling upside risk potential of 162.71%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than Geron, analysts believe Theriva Biologics is more attractive than Geron.

Geron has a beta of 0.645, which suggesting that the stock is 35.492% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Geron has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Geron quarterly revenues are $39.6M, which are larger than Theriva Biologics quarterly revenues of --. Geron's net income of -$19.8M is lower than Theriva Biologics's net income of -$4.3M. Notably, Geron's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron is 7.34x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.